Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a study in chronic kidney disease patients for nimacimab

Next Previous
Trial Profile

A Phase 2a study in chronic kidney disease patients for nimacimab

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimacimab (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Skye Bioscience

Most Recent Events

  • 11 Dec 2023 According to a skye bioscience media release, Company has filed an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase 2 clinical study of nimacimab in patients with obesity and chronic kidney disease.
  • 27 Aug 2023 New trial record
  • 21 Aug 2023 According to a skye bioscience media release, this phase 2a chronic kidney disease study expected to start in Q1 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top